In Taiwan, combined serum AFP levels and ultrasonography have been used for surveillance in patients with chronic HBV and HCV infections in intervals of 3–6 and 6–12 months for cirrhosis and chronic liver disease, respectively [44,45]. The gene discussed is AFP; the disease is Cirrhosis.